Isopropyl myristate:
the quiet 5 out of 5

Isopropyl myristate is the ester formed from isopropyl alcohol and myristic acid (a 14-carbon saturated fatty acid). It is a clear, low-viscosity, low-odour liquid that mixes readily with most cosmetic oils and many cosmetic alcohols, and it has a long shelf life. From a formulator's standpoint, it is a near-ideal slip and texture modifier. It softens the heavy feel of mineral oils and silicones, brings down the viscosity of thick emulsions, and gives a finished product the kind of glide that consumers consistently rate as "luxurious" in sensory testing.

It also has a less-obvious property: it is a penetration enhancer. Cosmetic and pharmaceutical research has documented IPM's ability to increase the percutaneous absorption of co-formulated actives by disrupting the lipid order of the stratum corneum. This is why you find it in some transdermal drug formulations and why it appears in many topical products that want to push actives like vitamins and antioxidants deeper into the skin. Penetration enhancement is not, in itself, a flaw, but it is part of the reason IPM-rich formulations can carry a bigger downstream impact than their bulk emollient role would suggest.

The third reason for IPM's ubiquity is cost. It is inexpensive to produce, available at high purity, and stable in formulation. For a formulator deciding between IPM and a more expensive ester or a synthetic squalane, the economics often favour IPM, especially in mass-market lines where margins are tight. None of this is malicious. It is the same set of trade-offs that drives every commodity ingredient in every consumer category. The cost is borne mainly by the subset of users whose skin reacts to it.

What you should take from this is calibration, not condemnation. IPM is in your products because it does multiple useful things at low cost. Whether it belongs in your routine specifically is a question your skin has to answer.

The original comedogenicity testing that established IPM's reputation was carried out by Kligman and colleagues in the late 1960s and 1970s, using the rabbit ear assay described in Kligman's 1972 paper in the Archives of Dermatology. Substances were applied to the inner ear of New Zealand white rabbits over several weeks, and the resulting follicles were biopsied and counted for comedones. IPM produced reliable, severe comedone formation in this model, placing it at the top of the resulting tables.

Subsequent work confirmed that the comedogenic effect was not limited to rabbits. Mills and Kligman published follow-up studies in the late 1970s testing several of the high-rated rabbit-ear ingredients on human subjects with comedonal acne. IPM continued to perform as a strong comedogen in those human studies, with reproducible follicular changes within weeks of repeated application. The convergence between the rabbit and human results is part of why IPM's high rating has stuck across decades, where the ratings of some other ingredients have been revised down as the assay's limitations became clearer.

It is worth being explicit about what these ratings mean and do not mean. They mean that IPM, applied in meaningful concentrations to receptive skin over a period of weeks, produces comedones at a high rate. They do not mean that every product containing IPM will give every user comedones. Concentration matters. The position of IPM in an ingredient list (third versus thirtieth) is informative. The rest of the formulation matters: an IPM-containing product with a heavy occlusive layer is going to behave differently than a light IPM-containing serum.

The clinical signal that maps to IPM sensitivity is closed comedones, those small, flesh-coloured or slightly raised bumps under the skin surface that do not come to a head. They cluster on the forehead, the cheeks, the chin, and the jawline, and they tend to develop slowly over weeks rather than appearing acutely. If your acne pattern is dominated by closed comedones and you are using leave-on facial products, IPM is one of the highest-yield ingredients to audit first.

IPM does not stand alone. It is part of a broader family of fatty alcohol esters used in cosmetics, several of which share its high comedogenicity rating. Tracking only "isopropyl myristate" in your routine and ignoring the rest of the family will leave you with an incomplete picture.

Isopropyl palmitate is the closest sibling, the ester of isopropyl alcohol and palmitic acid (16 carbons instead of 14). It rates 4 out of 5 on Kligman's comedogenicity tables. Isopropyl isostearate rates similarly high. Both share IPM's structural pattern of an isopropyl group esterified to a saturated long-chain fatty acid, and both behave similarly on acne-prone skin. If you have flagged IPM as a trigger, treat these two as part of the same audit.

Myristyl myristate is a different structure (a fatty alcohol esterified to a fatty acid, both derived from C14), and it also rates highly on comedogenicity tables. Myristyl lactate, decyl oleate, and several other "fatty alcohol of fatty acid" esters appear at moderate to high ratings. Not every ester in this family is comedogenic, the relationship between molecular structure and follicular behaviour is not perfectly predictable, but the cluster of high-rated ingredients sharing the basic isopropyl-or-myristyl-of-saturated-fatty-acid structure is large enough that pattern recognition is useful.

For contrast, esters like cetyl alcohol, stearyl alcohol, and squalane (a saturated hydrocarbon, not technically an ester) rate low on comedogenicity scales and rarely show up in clinical reports of ester-driven acne. Caprylic/capric triglyceride, which is technically a triglyceride rather than a simple ester, also generally behaves well. The takeaway is not that all esters are problematic. It is that there is a specific subset, anchored by IPM and isopropyl palmitate, that is worth watching.

When you are scanning a label, the names to flag explicitly are: Isopropyl Myristate, Isopropyl Palmitate, Isopropyl Isostearate, Myristyl Myristate, Myristyl Lactate, and Decyl Oleate. Tagging products containing any of these in ClearSkin lets you analyse the family-level signal even when no single product alone produces a clear breakout pattern.

IPM's combination of low cost, light skin feel, and useful slip means it is everywhere. The categories where it appears most often, and where it is most worth scanning for, are facial moisturisers (especially "lightweight" or "oil-free" formulations, where IPM provides slip without heaviness), facial sunscreens (both chemical and mineral, where IPM helps disperse filters and improve aesthetics), primers and silicone-feel face products, liquid foundations and tinted moisturisers, lipsticks and lip glosses, and some oily-skin or oil-control cleansers where IPM helps solubilise sebum.

The "lightweight oil-free" category is where IPM most often surprises people. The product feels nothing like a heavy cream, the marketing emphasises how breathable and acne-friendly it is, and yet IPM is sitting near the top of the ingredient list. The mismatch between sensory perception (light, dry, gentle) and follicular behaviour (slow comedone accumulation over weeks) is exactly what makes IPM so easy to overlook. If you have ever had the experience of breaking out from a moisturiser that felt lighter than the one you replaced, IPM is a strong candidate for what changed.

In sunscreens, IPM serves a real formulation purpose, it disperses both UV filters and pigments smoothly, and it helps avoid the heavy occlusive feel that older sunscreens were notorious for. A non-trivial fraction of "this sunscreen made me break out" reports are actually IPM reports, even though the user (and sometimes the marketing) attributed the issue to chemical filters or zinc oxide.

In liquid foundations, IPM is used both for slip and to keep the formulation easy to spread. The volume of product applied to facial skin in a daily makeup routine is substantial, and the 8-to-12 hours of contact during the day gives the ester ample time to interact with follicles. For people who wear foundation daily and have closed-comedone acne, foundation formulation is one of the highest-leverage things to audit, and IPM is one of the highest-leverage ingredients within that audit.

The product categories where IPM is less likely to drive face acne are short-contact rinse-off products (cleansers, masks rinsed within minutes) and body products used away from acne-prone regions. The exposure profile, both contact time and skin location, matters as much as the ingredient itself.

IPM is one of the more rewarding ingredients to test with structured tracking, because the lag between exposure and visible comedones is long enough that memory cannot reliably reconstruct it, and because the product audit is unusually informative. Most people, on first audit, find IPM in two or three of their daily-use leave-on products and have not realised it.

Begin with a full routine audit. Pull every leave-on facial product (moisturisers, sunscreens, primers, foundations, tinted moisturisers, eye creams, serums) and check the ingredient lists for Isopropyl Myristate, Isopropyl Palmitate, Isopropyl Isostearate, Myristyl Myristate, Myristyl Lactate, and Decyl Oleate. Tag each containing product in ClearSkin. Make a note of where in the ingredient list each ester appears, the difference between "third from the top" and "twentieth" is meaningful for how aggressive your trial needs to be.

Run a four-to-eight week IPM-out trial. The longer window matters here because closed comedones develop slowly and resolve slowly. Replace IPM-containing leave-on products with formulations that omit the entire ester family flagged above. Hold the rest of your routine constant: same cleanser, same actives, same sunscreen brand if possible (or a comparable IPM-free alternative). Track skin daily, with specific attention to the forehead, cheeks, chin, and jawline, the regions where closed comedones cluster most often.

The signal you are looking for is a slow flattening of the closed-comedone burden. The texture of the skin smooths under your fingers before the visible improvement is dramatic in the mirror. Inflammatory lesions may also reduce, but the closed-comedone signal is the one most specifically tied to IPM-family exposure. If you see meaningful improvement by week six to eight, IPM is a contributor for you. If you do not, it is unlikely to be a major driver, and the audit has at least cleared one significant variable from the table.

The reintroduction phase is informative but optional. Reintroducing one IPM-containing product at a time, with two to three weeks between reintroductions, lets you map your tolerance at the per-product level. Some people find they can tolerate IPM at low concentrations (deep in the ingredient list) but not high; some find they react to any IPM-containing leave-on face product. ClearSkin's per-product, per-ingredient tagging is built for exactly this kind of multi-week audit, the timeline view is what makes the slow-developing pattern legible.